DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

Patients might not know about Roche Tissue Diagnostics, but the Arizona entity has been testing for cancer and helping devise ...